ID   IDHC_HUMAN              Reviewed;         414 AA.
AC   O75874; Q567U4; Q6FHQ6; Q7Z3V0; Q93090; Q9NTJ9; Q9UKW8;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2002, sequence version 2.
DT   10-MAY-2017, entry version 184.
DE   RecName: Full=Isocitrate dehydrogenase [NADP] cytoplasmic;
DE            Short=IDH;
DE            EC=1.1.1.42;
DE   AltName: Full=Cytosolic NADP-isocitrate dehydrogenase;
DE   AltName: Full=IDP;
DE   AltName: Full=NADP(+)-specific ICDH;
DE   AltName: Full=Oxalosuccinate decarboxylase;
GN   Name=IDH1; Synonyms=PICD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9866202; DOI=10.1093/oxfordjournals.molbev.a025894;
RA   Nekrutenko A., Hillis D.M., Patton J.C., Bradley R.D., Baker R.J.;
RT   "Cytosolic isocitrate dehydrogenase in humans, mice, and voles and
RT   phylogenetic analysis of the enzyme family.";
RL   Mol. Biol. Evol. 15:1674-1684(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=10521434; DOI=10.1074/jbc.274.43.30527;
RA   Geisbrecht B.V., Gould S.J.;
RT   "The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-
RT   dependent isocitrate dehydrogenase.";
RL   J. Biol. Chem. 274:30527-30533(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 5-20; 30-49; 101-109; 120-132; 141-212; 223-233;
RP   250-270; 322-338 AND 389-400, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 100-253.
RA   Kullmann F., Vogt T., Welsh J., McClelland M.;
RT   "Differential gene expression in epithelial cells induced by bile
RT   salts: identification by RNA arbitrarily primed PCR.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-321, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-42, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEXES WITH NADP;
RP   ISOCITRATE AND CALCIUM IONS, AND SUBUNIT.
RX   PubMed=15173171; DOI=10.1074/jbc.M404298200;
RA   Xu X., Zhao J., Xu Z., Peng B., Huang Q., Arnold E., Ding J.;
RT   "Structures of human cytosolic NADP-dependent isocitrate dehydrogenase
RT   reveal a novel self-regulatory mechanism of activity.";
RL   J. Biol. Chem. 279:33946-33957(2004).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF VARIANT HIS-132 IN COMPLEX
RP   WITH NADP AND ALPHA-KETOGLUTARATE, CATALYTIC ACTIVITY, SUBUNIT,
RP   COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, CHARACTERIZATION OF VARIANTS
RP   CYS-132; HIS-132; LEU-132 AND SER-132, AND INVOLVEMENT IN GLM.
RX   PubMed=19935646; DOI=10.1038/nature08617;
RA   Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A.,
RA   Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C.,
RA   Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M.,
RA   Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G.,
RA   Su S.M.;
RT   "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.";
RL   Nature 462:739-744(2009).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-132.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [19]
RP   VARIANTS HIS-132 AND SER-132.
RX   PubMed=18772396; DOI=10.1126/science.1164382;
RA   Parsons D.W., Jones S., Zhang X., Lin J.C.-H., Leary R.J.,
RA   Angenendt P., Mankoo P., Carter H., Siu I.-M., Gallia G.L., Olivi A.,
RA   McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y.,
RA   Busam D.A., Tekleab H., Diaz L.A. Jr., Hartigan J., Smith D.R.,
RA   Strausberg R.L., Marie S.K.N., Shinjo S.M.O., Yan H., Riggins G.J.,
RA   Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G.,
RA   Vogelstein B., Velculescu V.E., Kinzler K.W.;
RT   "An integrated genomic analysis of human glioblastoma multiforme.";
RL   Science 321:1807-1812(2008).
RN   [20]
RP   VARIANTS CYS-132; GLY-132 AND LEU-132, AND INVOLVEMENT IN GLM.
RX   PubMed=19117336; DOI=10.1002/humu.20937;
RA   Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T.,
RA   Vandertop W.P., Frattini M., Molinari F., Knowles M., Cerrato A.,
RA   Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S.,
RA   Marchetti A., Bardelli A.;
RT   "IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in
RT   high-grade gliomas but not in other solid tumors.";
RL   Hum. Mutat. 30:7-11(2009).
RN   [21]
RP   VARIANTS CYS-132; GLY-132 AND HIS-132, INVOLVEMENT IN DISEASE, AND
RP   CHARACTERIZATIONOF VARIANT CYS-132.
RX   PubMed=26161668; DOI=10.1371/journal.pone.0131998;
RA   Jin Y., Elalaf H., Watanabe M., Tamaki S., Hineno S., Matsunaga K.,
RA   Woltjen K., Kobayashi Y., Nagata S., Ikeya M., Kato T. Jr.,
RA   Okamoto T., Matsuda S., Toguchida J.;
RT   "Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem
RT   Cells in Association with Gene-Specific Histone Modifications to
RT   Cartilage- and Bone-Related Genes.";
RL   PLoS ONE 10:E0131998-E0131998(2015).
CC   -!- CATALYTIC ACTIVITY: Isocitrate + NADP(+) = 2-oxoglutarate + CO(2)
CC       + NADPH. {ECO:0000269|PubMed:19935646}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:19935646};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:19935646};
CC       Note=Binds 1 Mg(2+) or Mn(2+) ion per subunit.
CC       {ECO:0000269|PubMed:19935646};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=49 uM for NADP {ECO:0000269|PubMed:19935646};
CC         KM=29 uM for magnesium chloride {ECO:0000269|PubMed:19935646};
CC         KM=65 uM for isocitrate {ECO:0000269|PubMed:19935646};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15173171,
CC       ECO:0000269|PubMed:19935646}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10521434}.
CC       Peroxisome {ECO:0000269|PubMed:10521434}.
CC   -!- PTM: Acetylation at Lys-374 dramatically reduces catalytic
CC       activity. {ECO:0000250}.
CC   -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or
CC       malignant central nervous system neoplasms derived from glial
CC       cells. They comprise astrocytomas and glioblastoma multiforme that
CC       are derived from astrocytes, oligodendrogliomas derived from
CC       oligodendrocytes and ependymomas derived from ependymocytes.
CC       {ECO:0000269|PubMed:19117336, ECO:0000269|PubMed:19935646}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. Mutations affecting Arg-132 are tissue-specific, and
CC       suggest that this residue plays a unique role in the development
CC       of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or
CC       Ser abolish magnesium binding and abolish the conversion of
CC       isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is
CC       converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2-
CC       hydroxyglutarate are correlated with an elevated risk of malignant
CC       brain tumors. {ECO:0000269|PubMed:19935646}.
CC   -!- DISEASE: Note=Genetic variations are associated with cartilaginous
CC       tumors such as enchondroma or chondrosarcoma. Mutations of Arg-132
CC       to Cys, Gly or His abolish the conversion of isocitrate to alpha-
CC       ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-
CC       2-hydroxyglutarate. {ECO:0000269|PubMed:26161668}.
CC   -!- SIMILARITY: Belongs to the isocitrate and isopropylmalate
CC       dehydrogenases family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Isocitrate dehydrogenase entry;
CC       URL="https://en.wikipedia.org/wiki/Isocitrate_dehydrogenase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF020038; AAD02918.1; -; mRNA.
DR   EMBL; AF113917; AAD29284.1; -; mRNA.
DR   EMBL; AL136702; CAB66637.1; -; mRNA.
DR   EMBL; CR541695; CAG46496.1; -; mRNA.
DR   EMBL; BX537411; CAD97653.1; -; mRNA.
DR   EMBL; AC016697; AAX93221.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70439.1; -; Genomic_DNA.
DR   EMBL; BC012846; AAH12846.1; -; mRNA.
DR   EMBL; BC093020; AAH93020.1; -; mRNA.
DR   EMBL; U62389; AAB17375.1; -; mRNA.
DR   CCDS; CCDS2381.1; -.
DR   PIR; T46280; T46280.
DR   RefSeq; NP_001269315.1; NM_001282386.1.
DR   RefSeq; NP_001269316.1; NM_001282387.1.
DR   RefSeq; NP_005887.2; NM_005896.3.
DR   UniGene; Hs.593422; -.
DR   PDB; 1T09; X-ray; 2.70 A; A/B=1-414.
DR   PDB; 1T0L; X-ray; 2.41 A; A/B/C/D=1-414.
DR   PDB; 3INM; X-ray; 2.10 A; A/B/C=1-414.
DR   PDB; 3MAP; X-ray; 2.80 A; A/B=1-414.
DR   PDB; 3MAR; X-ray; 3.41 A; A/B=1-414.
DR   PDB; 3MAS; X-ray; 3.20 A; A/B=1-414.
DR   PDB; 4I3K; X-ray; 3.31 A; A/B=1-414.
DR   PDB; 4I3L; X-ray; 3.29 A; A/B=1-414.
DR   PDB; 4KZO; X-ray; 2.20 A; A/B/C=1-414.
DR   PDB; 4L03; X-ray; 2.10 A; A/B/C=1-414.
DR   PDB; 4L04; X-ray; 2.87 A; A/B/C/D/E/F=1-414.
DR   PDB; 4L06; X-ray; 2.28 A; A/B/C/D/E/F=1-414.
DR   PDB; 4UMX; X-ray; 1.88 A; A/B=1-414.
DR   PDB; 4UMY; X-ray; 2.07 A; A/B=1-414.
DR   PDB; 4XRX; X-ray; 3.20 A; A/B=1-414.
DR   PDB; 4XS3; X-ray; 3.29 A; A/B=1-414.
DR   PDB; 5DE1; X-ray; 2.25 A; A/B=2-414.
DR   PDB; 5GIR; X-ray; 1.93 A; C/D=126-137.
DR   PDB; 5K10; EM; 3.80 A; A/B=3-413.
DR   PDB; 5K11; EM; 3.80 A; A/B=3-413.
DR   PDB; 5L57; X-ray; 2.69 A; A=1-414.
DR   PDB; 5L58; X-ray; 3.04 A; A=1-414.
DR   PDB; 5LGE; X-ray; 2.70 A; A/B/C/D=1-414.
DR   PDB; 5SUN; X-ray; 2.48 A; A/B=1-414.
DR   PDB; 5SVF; X-ray; 2.34 A; A/B/C/D=1-414.
DR   PDB; 5TQH; X-ray; 2.20 A; A/B/C/D=1-414.
DR   PDBsum; 1T09; -.
DR   PDBsum; 1T0L; -.
DR   PDBsum; 3INM; -.
DR   PDBsum; 3MAP; -.
DR   PDBsum; 3MAR; -.
DR   PDBsum; 3MAS; -.
DR   PDBsum; 4I3K; -.
DR   PDBsum; 4I3L; -.
DR   PDBsum; 4KZO; -.
DR   PDBsum; 4L03; -.
DR   PDBsum; 4L04; -.
DR   PDBsum; 4L06; -.
DR   PDBsum; 4UMX; -.
DR   PDBsum; 4UMY; -.
DR   PDBsum; 4XRX; -.
DR   PDBsum; 4XS3; -.
DR   PDBsum; 5DE1; -.
DR   PDBsum; 5GIR; -.
DR   PDBsum; 5K10; -.
DR   PDBsum; 5K11; -.
DR   PDBsum; 5L57; -.
DR   PDBsum; 5L58; -.
DR   PDBsum; 5LGE; -.
DR   PDBsum; 5SUN; -.
DR   PDBsum; 5SVF; -.
DR   PDBsum; 5TQH; -.
DR   ProteinModelPortal; O75874; -.
DR   SMR; O75874; -.
DR   BioGrid; 109643; 50.
DR   DIP; DIP-59311N; -.
DR   IntAct; O75874; 4.
DR   MINT; MINT-4998878; -.
DR   STRING; 9606.ENSP00000260985; -.
DR   BindingDB; O75874; -.
DR   ChEMBL; CHEMBL2007625; -.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB01727; Isocitric Acid.
DR   GuidetoPHARMACOLOGY; 2884; -.
DR   iPTMnet; O75874; -.
DR   PhosphoSitePlus; O75874; -.
DR   SwissPalm; O75874; -.
DR   BioMuta; IDH1; -.
DR   OGP; O75874; -.
DR   REPRODUCTION-2DPAGE; IPI00027223; -.
DR   UCD-2DPAGE; O75874; -.
DR   EPD; O75874; -.
DR   PaxDb; O75874; -.
DR   PeptideAtlas; O75874; -.
DR   PRIDE; O75874; -.
DR   DNASU; 3417; -.
DR   Ensembl; ENST00000345146; ENSP00000260985; ENSG00000138413.
DR   Ensembl; ENST00000415913; ENSP00000390265; ENSG00000138413.
DR   Ensembl; ENST00000446179; ENSP00000410513; ENSG00000138413.
DR   GeneID; 3417; -.
DR   KEGG; hsa:3417; -.
DR   CTD; 3417; -.
DR   DisGeNET; 3417; -.
DR   GeneCards; IDH1; -.
DR   H-InvDB; HIX0161877; -.
DR   HGNC; HGNC:5382; IDH1.
DR   HPA; CAB033218; -.
DR   HPA; CAB062556; -.
DR   HPA; HPA035248; -.
DR   HPA; HPA057936; -.
DR   MalaCards; IDH1; -.
DR   MIM; 137800; phenotype.
DR   MIM; 147700; gene.
DR   neXtProt; NX_O75874; -.
DR   OpenTargets; ENSG00000138413; -.
DR   Orphanet; 296; Enchondromatosis.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 163634; Maffucci syndrome.
DR   Orphanet; 99646; Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.
DR   PharmGKB; PA29630; -.
DR   eggNOG; KOG1526; Eukaryota.
DR   eggNOG; COG0538; LUCA.
DR   GeneTree; ENSGT00390000012547; -.
DR   HOGENOM; HOG000019858; -.
DR   HOVERGEN; HBG006119; -.
DR   InParanoid; O75874; -.
DR   KO; K00031; -.
DR   OMA; HNFESCG; -.
DR   OrthoDB; EOG091G06IY; -.
DR   PhylomeDB; O75874; -.
DR   TreeFam; TF300428; -.
DR   BioCyc; MetaCyc:HS06502-MONOMER; -.
DR   BRENDA; 1.1.1.42; 2681.
DR   Reactome; R-HSA-2978092; Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate.
DR   Reactome; R-HSA-389542; NADPH regeneration.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; O75874; -.
DR   ChiTaRS; IDH1; human.
DR   EvolutionaryTrace; O75874; -.
DR   GeneWiki; IDH1; -.
DR   GenomeRNAi; 3417; -.
DR   PRO; PR:O75874; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000138413; -.
DR   CleanEx; HS_IDH1; -.
DR   ExpressionAtlas; O75874; baseline and differential.
DR   Genevisible; O75874; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005782; C:peroxisomal matrix; TAS:Reactome.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0051990; F:(R)-2-hydroxyglutarate dehydrogenase activity; EXP:Reactome.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0004450; F:isocitrate dehydrogenase (NADP+) activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IEA:InterPro.
DR   GO; GO:0050661; F:NADP binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; IDA:UniProtKB.
DR   GO; GO:0008585; P:female gonad development; IEA:Ensembl.
DR   GO; GO:0006749; P:glutathione metabolic process; IEA:Ensembl.
DR   GO; GO:0006097; P:glyoxylate cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006102; P:isocitrate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006740; P:NADPH regeneration; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0071071; P:regulation of phospholipid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0060696; P:regulation of phospholipid catabolic process; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0048545; P:response to steroid hormone; IEA:Ensembl.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:UniProtKB-KW.
DR   InterPro; IPR019818; IsoCit/isopropylmalate_DH_CS.
DR   InterPro; IPR004790; Isocitrate_DH_NADP.
DR   InterPro; IPR024084; IsoPropMal-DH-like_dom.
DR   PANTHER; PTHR11822; PTHR11822; 1.
DR   Pfam; PF00180; Iso_dh; 1.
DR   PIRSF; PIRSF000108; IDH_NADP; 1.
DR   SMART; SM01329; Iso_dh; 1.
DR   TIGRFAMs; TIGR00127; nadp_idh_euk; 1.
DR   PROSITE; PS00470; IDH_IMDH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Glyoxylate bypass; Magnesium; Manganese;
KW   Metal-binding; NADP; Oxidoreductase; Peroxisome; Phosphoprotein;
KW   Polymorphism; Reference proteome; Tricarboxylic acid cycle.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    414       Isocitrate dehydrogenase [NADP]
FT                                cytoplasmic.
FT                                /FTId=PRO_0000083575.
FT   NP_BIND      75     77       NADP. {ECO:0000269|PubMed:19935646}.
FT   NP_BIND     310    315       NADP. {ECO:0000269|PubMed:19935646}.
FT   REGION       94    100       Substrate binding.
FT   METAL       252    252       Magnesium or manganese.
FT   METAL       275    275       Magnesium or manganese.
FT   BINDING      77     77       Substrate.
FT   BINDING      82     82       NADP. {ECO:0000269|PubMed:19935646}.
FT   BINDING     109    109       Substrate.
FT   BINDING     132    132       Substrate.
FT   BINDING     260    260       NADP. {ECO:0000269|PubMed:19935646}.
FT   BINDING     328    328       NADP; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000269|PubMed:19935646}.
FT   SITE        139    139       Critical for catalysis.
FT   SITE        212    212       Critical for catalysis.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES      42     42       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      81     81       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O88844}.
FT   MOD_RES     126    126       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:O88844}.
FT   MOD_RES     224    224       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O88844}.
FT   MOD_RES     233    233       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O88844}.
FT   MOD_RES     243    243       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O88844}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     389    389       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88844}.
FT   MOD_RES     400    400       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:O88844}.
FT   VARIANT     132    132       R -> C (in colorectal cancer and glioma
FT                                samples; glioblastoma multiforme; somatic
FT                                mutation; found in patients with
FT                                cartilaginous tumors; abolishes magnesium
FT                                binding and alters enzyme activity so
FT                                that isocitrate is no longer converted to
FT                                alpha-ketoglutarate but instead alpha-
FT                                ketoglutarate is converted to R(-)-2-
FT                                hydroxyglutarate; induces histone
FT                                methylation; enhances expression of
FT                                chondrocyte-related genes; disturbs the
FT                                formation of cartilaginous matrix;
FT                                inhibits osteogenic differentiation;
FT                                dbSNP:rs121913499).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:19117336,
FT                                ECO:0000269|PubMed:19935646,
FT                                ECO:0000269|PubMed:26161668}.
FT                                /FTId=VAR_036013.
FT   VARIANT     132    132       R -> G (in a glioma sample; glioblastoma
FT                                multiforme; somatic mutation; found in
FT                                patients with cartilaginous tumors).
FT                                {ECO:0000269|PubMed:19117336,
FT                                ECO:0000269|PubMed:26161668}.
FT                                /FTId=VAR_055454.
FT   VARIANT     132    132       R -> H (in a glioma sample; glioblastoma
FT                                multiforme; somatic mutation; found in
FT                                patients with cartilaginous tumors;
FT                                abolishes magnesium binding and alters
FT                                enzyme activity so that isocitrate is no
FT                                longer converted to alpha-ketoglutarate
FT                                but instead alpha-ketoglutarate is
FT                                converted to R(-)-2-hydroxyglutarate;
FT                                dbSNP:rs121913500).
FT                                {ECO:0000269|PubMed:18772396,
FT                                ECO:0000269|PubMed:19935646,
FT                                ECO:0000269|PubMed:26161668}.
FT                                /FTId=VAR_055455.
FT   VARIANT     132    132       R -> L (in a glioma sample; glioblastoma
FT                                multiforme; somatic mutation; abolishes
FT                                magnesium binding and alters enzyme
FT                                activity so that isocitrate is no longer
FT                                converted to alpha-ketoglutarate but
FT                                instead alpha-ketoglutarate is converted
FT                                to R(-)-2-hydroxyglutarate).
FT                                {ECO:0000269|PubMed:19117336,
FT                                ECO:0000269|PubMed:19935646}.
FT                                /FTId=VAR_055456.
FT   VARIANT     132    132       R -> S (in a glioma sample; glioblastoma
FT                                multiforme; somatic mutation; abolishes
FT                                magnesium binding and alters enzyme
FT                                activity so that isocitrate is no longer
FT                                converted to alpha-ketoglutarate but
FT                                instead alpha-ketoglutarate is converted
FT                                to R(-)-2-hydroxyglutarate;
FT                                dbSNP:rs121913499).
FT                                {ECO:0000269|PubMed:18772396,
FT                                ECO:0000269|PubMed:19935646}.
FT                                /FTId=VAR_055457.
FT   VARIANT     178    178       V -> I (in dbSNP:rs34218846).
FT                                /FTId=VAR_049780.
FT   CONFLICT     32     32       F -> I (in Ref. 3; CAB66637).
FT                                {ECO:0000305}.
FT   CONFLICT    126    126       K -> E (in Ref. 3; CAB66637).
FT                                {ECO:0000305}.
FT   CONFLICT    172    172       F -> S (in Ref. 5; CAD97653).
FT                                {ECO:0000305}.
FT   CONFLICT    174    174       E -> G (in Ref. 5; CAD97653).
FT                                {ECO:0000305}.
FT   CONFLICT    218    218       K -> I (in Ref. 1; AAD02918).
FT                                {ECO:0000305}.
FT   CONFLICT    307    307       A -> S (in Ref. 6; AAH93020).
FT                                {ECO:0000305}.
FT   CONFLICT    329    329       P -> L (in Ref. 1; AAD02918).
FT                                {ECO:0000305}.
FT   CONFLICT    381    381       K -> R (in Ref. 1; AAD02918).
FT                                {ECO:0000305}.
FT   STRAND        5     14       {ECO:0000244|PDB:4UMX}.
FT   HELIX        17     29       {ECO:0000244|PDB:4UMX}.
FT   TURN         30     34       {ECO:0000244|PDB:4UMX}.
FT   STRAND       35     43       {ECO:0000244|PDB:4UMX}.
FT   HELIX        46     51       {ECO:0000244|PDB:4UMX}.
FT   TURN         52     54       {ECO:0000244|PDB:4UMX}.
FT   HELIX        55     67       {ECO:0000244|PDB:4UMX}.
FT   STRAND       68     72       {ECO:0000244|PDB:4UMX}.
FT   HELIX        80     86       {ECO:0000244|PDB:4UMX}.
FT   HELIX        95    103       {ECO:0000244|PDB:4UMX}.
FT   STRAND      105    111       {ECO:0000244|PDB:4UMX}.
FT   STRAND      126    134       {ECO:0000244|PDB:4UMX}.
FT   HELIX       137    140       {ECO:0000244|PDB:3INM}.
FT   STRAND      142    146       {ECO:0000244|PDB:4UMX}.
FT   STRAND      148    158       {ECO:0000244|PDB:4UMX}.
FT   STRAND      165    172       {ECO:0000244|PDB:4UMX}.
FT   STRAND      177    185       {ECO:0000244|PDB:4UMX}.
FT   HELIX       186    203       {ECO:0000244|PDB:4UMX}.
FT   STRAND      207    210       {ECO:0000244|PDB:4UMX}.
FT   TURN        213    215       {ECO:0000244|PDB:4UMX}.
FT   HELIX       219    234       {ECO:0000244|PDB:4UMX}.
FT   HELIX       236    241       {ECO:0000244|PDB:4UMX}.
FT   STRAND      246    248       {ECO:0000244|PDB:4UMX}.
FT   HELIX       251    259       {ECO:0000244|PDB:4UMX}.
FT   STRAND      263    269       {ECO:0000244|PDB:4UMX}.
FT   STRAND      271    273       {ECO:0000244|PDB:5LGE}.
FT   HELIX       276    278       {ECO:0000244|PDB:4UMX}.
FT   HELIX       280    284       {ECO:0000244|PDB:4UMX}.
FT   HELIX       288    290       {ECO:0000244|PDB:4UMX}.
FT   STRAND      291    296       {ECO:0000244|PDB:4UMX}.
FT   STRAND      303    309       {ECO:0000244|PDB:4UMX}.
FT   HELIX       313    320       {ECO:0000244|PDB:4UMX}.
FT   HELIX       330    347       {ECO:0000244|PDB:4UMX}.
FT   HELIX       350    368       {ECO:0000244|PDB:4UMX}.
FT   HELIX       374    381       {ECO:0000244|PDB:4UMX}.
FT   HELIX       383    385       {ECO:0000244|PDB:4UMX}.
FT   HELIX       388    390       {ECO:0000244|PDB:4UMX}.
FT   HELIX       394    413       {ECO:0000244|PDB:4UMX}.
SQ   SEQUENCE   414 AA;  46659 MW;  60428B0B6E5851DC CRC64;
     MSKKISGGSV VEMQGDEMTR IIWELIKEKL IFPYVELDLH SYDLGIENRD ATNDQVTKDA
     AEAIKKHNVG VKCATITPDE KRVEEFKLKQ MWKSPNGTIR NILGGTVFRE AIICKNIPRL
     VSGWVKPIII GRHAYGDQYR ATDFVVPGPG KVEITYTPSD GTQKVTYLVH NFEEGGGVAM
     GMYNQDKSIE DFAHSSFQMA LSKGWPLYLS TKNTILKKYD GRFKDIFQEI YDKQYKSQFE
     AQKIWYEHRL IDDMVAQAMK SEGGFIWACK NYDGDVQSDS VAQGYGSLGM MTSVLVCPDG
     KTVEAEAAHG TVTRHYRMYQ KGQETSTNPI ASIFAWTRGL AHRAKLDNNK ELAFFANALE
     EVSIETIEAG FMTKDLAACI KGLPNVQRSD YLNTFEFMDK LGENLKIKLA QAKL
//
